Global Drug Coated Balloon Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Drug Coated Balloon Market Overview

The Drug Coated Balloon Market was valued at USD 1.87 billion in 2025 and is projected to reach USD 3.14 billion by 2033, growing at a CAGR of 6.7% from 2026 to 2033. The market is experiencing significant growth driven by the increasing prevalence of cardiovascular diseases, rising demand for minimally invasive vascular interventions, and continuous advancements in drug delivery and balloon catheter technologies.

The growing burden of peripheral artery disease (PAD) and coronary artery disease (CAD), combined with increasing preference for restenosis prevention therapies and shorter hospital stays, is encouraging hospitals, cardiac centers, and healthcare providers to adopt advanced drug coated balloon technologies. Paclitaxel-coated and sirolimus-coated balloons are increasingly being utilized as alternatives to conventional stenting procedures in many clinical settings, offering targeted drug delivery, reduced risk of permanent implant complications, and improved vascular healing outcomes.

Key Market Trends & Insights

• North America dominated the Drug Coated Balloon Market with the largest revenue share of 38.42% in 2025, supported by advanced cardiovascular treatment infrastructure, high adoption of minimally invasive procedures, and strong presence of leading medical device manufacturers.
• The Peripheral drug-coated balloons segment led the market with a 44.36% share in 2025, driven by increasing prevalence of peripheral artery disease and growing preference for endovascular treatment procedures.
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 7.5% from 2026 to 2033, fueled by rising cardiovascular disease burden, expanding healthcare infrastructure, and increasing adoption of advanced interventional cardiology procedures in China, India, and Japan.
• Sirolimus-Coated Balloons are the fastest-growing drug type, projected to register a CAGR of 7.3%, reflecting growing demand for safer and more effective alternatives with improved vascular healing profiles.
• The Coronary Artery Disease segment dominated the application category with a 39.84% revenue share in 2025, led by increasing incidence of coronary blockages, restenosis cases, and rising demand for minimally invasive angioplasty procedures.
• Hospital-based procedures account for 61.27% of the market, preferred due to availability of specialized catheterization laboratories, skilled interventional cardiologists, and advanced post-procedural care infrastructure.
• The AI & Imaging-Guided Analytics segment is the fastest-growing technology category, with a CAGR of 7.1%, driven by increasing integration of real-time imaging, lesion assessment tools, and precision-based vascular intervention platforms.

Market Size & Forecast

• Global Market Value (2025): USD 1.87 Billion
• Expected Market Value (2033): USD 3.14 Billion
• Forecast CAGR (2026–2033): 6.7%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia-Pacific

Report Scope and Drug Coated Balloon Market Segmentation

Drug Coated Balloon Market Trends

Trend: Increasing Adoption of Drug-Coated Balloons in Peripheral Artery Disease Treatment

Healthcare providers and cardiovascular specialists are increasingly adopting drug coated balloons for the treatment of peripheral artery disease (PAD) and in-stent restenosis due to their ability to deliver targeted drug therapy without leaving permanent implants inside the vessel. The integration of advanced drug delivery coatings and improved balloon catheter technologies enables enhanced vascular healing and reduced rates of repeat interventions. Hospitals and cardiac centers are similarly utilizing next-generation paclitaxel- and sirolimus-coated balloons to improve procedural outcomes through minimally invasive and data-driven treatment approaches, while advances in imaging-guided interventions are enhancing precision during angioplasty procedures.

Drug Coated Balloon Market Dynamics

Key Market Driver: Rising Prevalence of Cardiovascular and Peripheral Artery Diseases

The increasing global burden of cardiovascular diseases, peripheral artery disease (PAD), and coronary artery disease (CAD) has created substantial demand for minimally invasive vascular intervention procedures, including drug coated balloon angioplasty. Hospitals, cardiac catheterization laboratories, and interventional cardiology centers are increasingly deploying drug coated balloons as an effective alternative to conventional stenting procedures, reducing restenosis risk, improving blood vessel patency, and enhancing patient recovery outcomes. Growing adoption of advanced endovascular therapies and increasing preference for implant-free treatment solutions are further accelerating market growth.

Key Restraint/Challenge: High Cost of Drug-Coated Balloon Procedures and Limited Reimbursement

A significant restraint in the Drug Coated Balloon Market is the high procedural and device cost associated with advanced coated balloon technologies. Modern drug coated balloons integrate specialized anti-proliferative drug coatings, sophisticated catheter engineering, and controlled drug-release mechanisms, resulting in higher procurement costs compared to conventional balloon angioplasty devices. The overall treatment cost further increases due to specialized imaging systems, skilled interventional cardiologists, and post-procedure monitoring requirements, limiting adoption across smaller healthcare facilities and cost-sensitive emerging markets.

The 2024 expansion of advanced sirolimus-coated balloon clinical studies across Europe and Asia highlighted the substantial investment required for product development, regulatory approvals, and long-term safety validation, reflecting the broader challenge of balancing innovation costs with large-scale market accessibility.

Key Market Opportunity: Development of Next-Generation Sirolimus-Coated Balloon Technologies

The development of next-generation sirolimus-coated balloon technologies presents a significant market opportunity. Advanced sirolimus-based platforms offer improved drug transfer efficiency, enhanced vessel healing properties, and reduced thrombosis risks compared to earlier-generation paclitaxel-coated devices. The integration of precision imaging technologies, AI-assisted lesion assessment tools, and minimally invasive endovascular treatment platforms is further improving procedural outcomes and expanding clinical applications. In addition, growing healthcare investments and increasing adoption of advanced cardiovascular intervention technologies across Asia-Pacific, Latin America, and the Middle East are creating substantial growth opportunities for market participants.

Drug Coated Balloon Market Scope

The drug coated balloons market is segmented on the basis of product type, drug type, application, end user, balloon material, technology, procedure type, delivery platform, deployment mode, distribution channel, and support & services.

• By Product Type

On the basis of product type, the Drug Coated Balloon Market is segmented into coronary drug-coated balloons, peripheral drug-coated balloons, neurovascular drug-coated balloons, and urological drug-coated balloons. The peripheral drug-coated balloons segment dominated the market with a share of 44.36% in 2025, owing to the rising prevalence of peripheral artery disease (PAD), increasing preference for minimally invasive vascular interventions, and growing use of drug coated balloons in lower limb revascularization procedures. These balloons provide targeted drug delivery without leaving permanent implants, making them the preferred choice for interventional cardiologists and vascular specialists.

The coronary drug-coated balloons segment is projected to register the fastest growth at a CAGR of 7.1% from 2026 to 2033, driven by increasing adoption in coronary artery disease treatment and in-stent restenosis management. Advancements in balloon catheter technologies, improved drug delivery efficiency, and rising clinical preference for stent-free interventions are accelerating segment expansion.

• By Drug Type

On the basis of drug type, the Drug Coated Balloon Market is segmented into paclitaxel-coated balloons, sirolimus-coated balloons, and other drug-coated balloons. The paclitaxel-coated balloons segment led the market with a 58.42% share in 2025, supported by strong clinical adoption, established regulatory approvals, and extensive use in peripheral and coronary angioplasty procedures globally.

The sirolimus-coated balloons segment is expected to experience the fastest growth at a CAGR of 7.3% from 2026 to 2033, driven by increasing demand for safer anti-restenotic therapies, improved vessel healing properties, and growing clinical evidence supporting sirolimus-based drug delivery technologies.

• By Application

On the basis of application, the Drug Coated Balloon Market is segmented into coronary artery disease, peripheral artery disease, in-stent restenosis, hemodialysis access disease, and others. The coronary artery disease segment dominated the market with a share of 39.84% in 2025 due to the increasing incidence of coronary blockages, growing number of angioplasty procedures, and rising adoption of minimally invasive cardiovascular treatment technologies. additionally, increasing focus on reducing repeat interventions and improving long-term vessel patency is supporting the widespread adoption of drug coated balloons in coronary procedures.

The in-stent restenosis segment is anticipated to witness the fastest CAGR of 7.0% from 2026 to 2033, driven by the increasing prevalence of restenosis complications following stent implantation and growing clinical preference for drug coated balloon therapy as an effective treatment alternative. additionally, advancements in drug coating technologies and expanding use in repeat coronary interventions are further driving segment growth.

• By End User

On the basis of end user, the Drug Coated Balloon Market is segmented into hospitals, cardiac catheterization laboratories, ambulatory surgical centers, and specialty clinics. The hospitals segment dominated the market with a share of 47.68% in 2025 due to the high volume of cardiovascular intervention procedures, availability of advanced imaging and catheterization infrastructure, and presence of skilled interventional cardiologists. the increasing adoption of minimally invasive vascular procedures and growing investment in cardiovascular treatment technologies are reinforcing the dominance of this segment across global healthcare markets.

The cardiac catheterization laboratories segment is expected to witness the fastest CAGR of 6.9% from 2026 to 2033, driven by the rising number of specialized cardiovascular treatment centers and increasing demand for advanced angioplasty and vascular intervention procedures. additionally, growing integration of imaging-guided technologies and real-time lesion assessment tools is further accelerating segment growth.

• By Balloon Material

On the basis of balloon material, the Drug Coated Balloon Market is segmented into semi-compliant balloons and non-compliant balloons. The semi-compliant balloons segment dominated the market with a share of 57.14% in 2025 due to their flexibility, ease of navigation through complex vascular anatomies, and widespread use across peripheral and coronary angioplasty procedures. high adoption is driven by increasing preference for controlled lesion dilation and improved procedural safety during minimally invasive interventions.

The non-compliant balloons segment is expected to witness the fastest CAGR of 6.8% from 2026 to 2033, driven by increasing demand for high-pressure dilation procedures and improved precision during complex coronary interventions. additionally, advancements in balloon engineering technologies are enhancing procedural efficiency and treatment outcomes.

• By Technology

On the basis of technology, the Drug Coated Balloon Market is segmented into single-coating technology, dual-coating technology, and controlled drug release technology. The single-coating technology segment dominated the market with a share of 48.26% in 2025 due to its widespread clinical adoption, manufacturing simplicity, and proven effectiveness in delivering anti-proliferative drugs during angioplasty procedures. additionally, increasing regulatory approvals and established physician familiarity are reinforcing the leading position of this segment in the market.

The controlled drug release technology segment is expected to witness the fastest CAGR of 7.2% from 2026 to 2033, driven by increasing demand for improved drug transfer efficiency, prolonged therapeutic effect, and enhanced vascular healing outcomes. these technologies enable optimized drug retention and reduced systemic exposure, accelerating adoption across advanced cardiovascular intervention procedures.

• By Procedure Type

On the basis of procedure type, the Drug Coated Balloon Market is segmented into de novo lesions, in-stent restenosis procedures, and chronic total occlusion procedures. The de novo lesions segment dominated the market with a share of 45.31% in 2025 due to the rising number of first-time angioplasty procedures and increasing use of drug coated balloons in minimally invasive vascular treatments. high adoption is supported by growing preference for implant-free therapies and improved procedural outcomes.

The in-stent restenosis procedures segment is expected to witness the fastest CAGR of 7.1% from 2026 to 2033, driven by increasing incidence of restenosis after stent implantation and growing clinical recommendations supporting drug coated balloon therapy for repeat vascular interventions.

• By Delivery Platform

On the basis of delivery platform, the Drug Coated Balloon Market is segmented into rapid exchange systems and over-the-wire systems. The rapid exchange systems segment dominated the market with a share of 61.22% in 2025 due to ease of use, reduced procedural time, and growing preference among interventional cardiologists for simplified catheter delivery systems. additionally, these systems improve maneuverability and procedural efficiency during complex angioplasty procedures.

The over-the-wire systems segment is expected to witness the fastest CAGR of 6.7% from 2026 to 2033, driven by increasing use in highly complex vascular interventions requiring enhanced guidewire support and precise balloon positioning capabilities.

• By Deployment Mode

On the basis of deployment mode, the Drug Coated Balloon Market is segmented into hospital-based procedures and outpatient procedures. The hospital-based procedures segment dominated the market with a share of 63.45% in 2025 due to the availability of advanced cardiovascular treatment infrastructure, skilled specialists, and integrated emergency care support. additionally, increasing volume of angioplasty and vascular intervention procedures performed in hospitals is reinforcing this segment’s leading market position.

The outpatient procedures segment is expected to witness the fastest CAGR of 6.8% from 2026 to 2033, driven by increasing demand for cost-effective minimally invasive treatments, shorter recovery periods, and growing adoption of ambulatory cardiovascular care services.

• By Distribution Channel

On the basis of distribution channel, the Drug Coated Balloon Market is segmented into direct tenders, third-party distributors, and retail sales. The direct tenders segment dominated the market with a share of 52.63% in 2025 due to strong procurement agreements between manufacturers and hospitals, large-scale purchasing by healthcare institutions, and improved supply chain efficiency. additionally, direct procurement enables cost optimization and consistent product availability across high-volume healthcare facilities.

The third-party distributors segment is expected to witness the fastest CAGR of 6.6% from 2026 to 2033, driven by expanding market penetration strategies, increasing geographic reach in emerging economies, and growing collaborations between manufacturers and regional medical device distributors.

• By Support & Services

On the basis of support & services, the Drug Coated Balloon Market is segmented into product training & education, technical support services, maintenance & upgrades, and consulting services. The product training & education segment dominated the market with a share of 36.18% in 2025 due to the increasing need for physician training on advanced angioplasty procedures, drug delivery mechanisms, and minimally invasive intervention techniques. the widespread presence of manufacturer-led training initiatives and clinical education programs is reinforcing the leading position of this segment in the global market.

The technical support services segment is expected to witness the fastest CAGR of 6.5% from 2026 to 2033, driven by the increasing adoption of technologically advanced balloon catheter systems and growing demand for real-time procedural support, device troubleshooting, and clinical guidance during cardiovascular interventions.

Drug Coated Balloon Market Regional Analysis

North America dominated the drug coated balloon market and accounted for the largest revenue share of 38.42% in 2025, supported by advanced cardiovascular treatment infrastructure, strong adoption of minimally invasive vascular intervention procedures, and the presence of leading medical device manufacturers. The region also benefits from increasing prevalence of peripheral artery disease and coronary artery disease, favorable reimbursement frameworks, and growing use of technologically advanced angioplasty devices across hospitals and cardiac centers. Increasing focus on reducing restenosis rates and improving patient outcomes continues to strengthen North America’s leadership position in the global market.

U.S. Drug Coated Balloon Market Insight

The U.S. drug coated balloon market is witnessing strong growth due to rising prevalence of cardiovascular diseases, increasing adoption of minimally invasive angioplasty procedures, and growing investments in advanced vascular intervention technologies. The country’s mature healthcare infrastructure, along with increasing use of imaging-guided procedures and next-generation sirolimus-coated balloon systems, is driving demand across hospitals, cardiac catheterization laboratories, and specialty cardiovascular centers. In addition, growing emphasis on reducing repeat revascularization procedures and improving long-term vessel patency is accelerating market expansion across the United States.

Europe Drug Coated Balloon Market Insight

The Europe drug coated balloon market remains a major contributor to global revenue, driven by strong regulatory support for advanced cardiovascular therapies, technological innovation, and increasing demand for minimally invasive vascular treatments. The widespread use of drug coated balloons in peripheral artery disease and in-stent restenosis treatment procedures is supporting market expansion across the region. Increasing investments in advanced catheter technologies, combined with growing adoption of sirolimus-coated balloon systems and a highly developed healthcare ecosystem, continue to enhance the adoption of drug coated balloons throughout Europe.

U.K. Drug Coated Balloon Market Insight

The U.K. drug coated balloon market is experiencing steady growth, supported by rising prevalence of cardiovascular disorders, increasing adoption of minimally invasive angioplasty procedures, and growing investments in advanced interventional cardiology technologies. Increasing focus on improving patient recovery outcomes and reducing hospitalization periods is contributing to market growth. Furthermore, integration of precision imaging systems and advanced vascular intervention technologies is improving procedural efficiency and positioning the U.K. as a key innovation hub in the cardiovascular device industry.

Germany Drug Coated Balloon Market Insight

The Germany drug coated balloon market is expanding steadily due to the country’s strong medical device manufacturing base, advanced cardiovascular research capabilities, and increasing adoption of next-generation vascular intervention technologies. Hospitals, research institutions, and cardiovascular treatment centers are increasingly utilizing drug coated balloons for coronary and peripheral angioplasty procedures. Continuous advancements in balloon coating technologies, precision catheter systems, and imaging-guided interventions, along with strong government focus on healthcare innovation and cardiovascular disease management, are further driving market growth in Germany.

Asia-Pacific Drug Coated Balloon Market Insight

The Asia-Pacific drug coated balloon market is expected to witness rapid growth, driven by increasing prevalence of cardiovascular diseases, expanding healthcare infrastructure, and rising investments in interventional cardiology across countries such as China, India, and Japan. Growing awareness regarding minimally invasive treatment procedures, rising adoption of advanced angioplasty technologies, and increasing demand for cost-effective cardiovascular therapies are supporting regional market expansion. Additionally, the growing presence of medical device manufacturers and increasing healthcare expenditure are accelerating drug coated balloon adoption across hospitals and specialty cardiovascular centers.

Japan Drug Coated Balloon Market Insight

The Japan drug coated balloon market is witnessing consistent growth due to rising investments in advanced cardiovascular treatment technologies, increasing prevalence of coronary artery disease, and growing demand for minimally invasive intervention procedures. Hospitals, research institutes, and cardiovascular specialists are increasingly adopting high-performance drug coated balloons for vascular treatment and restenosis management purposes. Moreover, increasing integration of precision imaging technologies and the country’s focus on improving cardiovascular healthcare outcomes are further contributing to market growth.

China Drug Coated Balloon Market Insight

The China drug coated balloon market is growing rapidly, driven by increasing urbanization, expanding healthcare infrastructure, and rising government focus on cardiovascular disease management and minimally invasive treatment adoption. Growing use of sirolimus-coated and paclitaxel-coated balloon systems across hospitals and cardiac centers is significantly boosting market demand. In addition, rising investments in medical device manufacturing, increasing awareness regarding advanced vascular intervention procedures, and rapid technological advancements are positioning China as one of the fastest-growing markets for drug coated balloons globally.

Drug Coated Balloon Market Share

The drug coated balloon industry is primarily led by well-established companies, including:

• Medtronic plc (Ireland)
• Boston Scientific Corporation (U.S.)
• Becton, Dickinson and Company (U.S.)
• Koninklijke Philips N.V. (Netherlands)
• Braun SE (Germany)
• BIOTRONIK SE & Co. KG (Germany)
• Terumo Corporation (Japan)
• Cook Medical (U.S.)
• Cordis (U.S.)
• Meril Life Sciences Pvt. Ltd. (India)
• MicroPort Scientific Corporation (China)
• Concept Medical Inc. (India)
• Acotec Scientific Holdings Limited (China)
• Cardionovum GmbH (Germany)
• Opto Circuits Limited (India)
• Lepu Medical Technology Co., Ltd. (China)
• iVascular S.L.U. (Spain)
• BrosMed Medical Co., Ltd. (China)
• Surmodics, Inc. (U.S.)
• Endocor GmbH (Germany)
• QT Vascular Ltd. (Singapore)
• Eurocor Tech GmbH (Germany)
• Aachen Resonance GmbH (Germany)
• Balton Sp. z o.o. (Poland)
• Translumina Therapeutics LLP (India)

Latest Developments in Drug Coated Balloon Market

• In February 2025, Boston Scientific Corporation expanded the commercial availability of its AGENT Drug-Coated Balloon in additional international markets following growing physician adoption for the treatment of coronary in-stent restenosis. The device utilizes paclitaxel coating technology designed to reduce restenosis risk while avoiding permanent implant placement. The expansion strengthens Boston Scientific’s position in the Drug Coated Balloon Market by increasing access to minimally invasive coronary intervention solutions and enhancing its cardiovascular therapy portfolio.
• In January 2025, Medtronic plc announced advancements in its peripheral vascular intervention portfolio through the integration of next-generation drug delivery technologies for complex arterial disease treatment. The company focused on improving balloon coating uniformity, drug transfer efficiency, and procedural precision to enhance long-term vessel patency outcomes. These developments reinforce Medtronic’s strategic presence in the drug coated balloon market by supporting innovation in minimally invasive endovascular therapies.
• In October 2024, Becton, Dickinson and Company expanded clinical evaluation programs for advanced sirolimus-coated balloon technologies aimed at improving treatment outcomes in peripheral artery disease and coronary artery disease procedures. The initiative focuses on enhancing anti-restenotic performance, reducing late lumen loss, and improving vascular healing profiles. This development highlights the growing industry transition toward next-generation sirolimus-based drug coated balloon platforms for cardiovascular interventions.
• In July 2024, Concept Medical Inc. received expanded international recognition for its sirolimus-coated balloon platform designed for coronary and peripheral vascular interventions. The technology incorporates controlled drug-release mechanisms and advanced coating architecture to improve drug retention and vessel healing efficiency. The expansion strengthens Concept Medical’s competitive position in the drug coated balloon market while accelerating adoption of implant-free angioplasty solutions across global healthcare systems.
• In March 2023, BIOTRONIK launched new clinical initiatives focused on evaluating the effectiveness of drug coated balloon therapy in complex coronary artery disease and small vessel interventions. The studies aimed to assess long-term procedural safety, reduction in restenosis incidence, and improved patient recovery outcomes through minimally invasive treatment approaches. This development demonstrates the growing clinical emphasis on expanding the use of drug coated balloons across advanced cardiovascular intervention applications.

SKU-75968